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A new and exciting phase of muscle disease research has recently been
entered. The application of next generation sequencing technology has
spurred an unprecedented era of gene discovery for both myopathies and
muscular dystrophies. Gene-based therapies for Duchenne muscular dystro-
phy have entered clinical trial, and several pathway-based therapies are
doing so as well for a handful of muscle diseases. While many factors have
aided the extraordinary developments in gene discovery and therapy devel-
opment, the zebrafish model system has emerged as a vital tool in these
advancements. In this review, we will highlight how the zebrafish has
greatly aided in the identification of new muscle disease genes and in the
recognition of novel therapeutic strategies. We will start with a general
introduction to the zebrafish as a model, discuss the ways in which muscle
disease can be modeled and analyzed in the fish, and conclude with obser-
vations from recent studies that highlight the power of the fish as a
research tool for muscle disease.
Why zebrafish?
There are numerous factors that make zebrafish a
particularly appealing model organism. Such advan-
tages have been extensively enumerated in several
outstanding recent reviews and include especially (a)
the ability to quickly generate a large number of off-
spring (100–300 embryos per cross), (b) the rapid ex
utero development of the zebrafish, (c) the optical
transparency of zebrafish embryos and larvae, (d)
the ease of genetic manipulations and (e) the ready
ability of the zebrafish embryo to absorb drugs [1,2].
In addition, zebrafish offer several specific qualities
as a model for human muscle disorders. They have
reproducible, quantitative and easily measured motor
behaviors that are present from 1 day of life
onward. Their skeletal muscle shares many molecular
and histological features with mammalian muscle
(Fig. 1A–C) and appears nearly identical to human
muscle at the ultrastructural level. This includes pres-
ervation of the components of the dystrophin-associ-
ated glycoprotein complex, the excitation–contraction
coupling machinery and the contractile apparatus,
three fundamental muscle structures that are key to
studying and understanding human muscle disease
pathogenesis [3–7]. In addition, skeletal muscle is the
largest and most prominent organ system of the
developing zebrafish and, due to the optical trans-
parency of the zebrafish, can be easily visualized in
live animals. Finally, the phenotypes of several ze-
brafish models more closely approximate the severity
of the human clinical presentation than correspond-
ing mouse models [8–10]. For example, dystrophin-
deficient zebrafish exhibit a severe motor phenotype
by 4 days of life and die by 2 weeks of life, while
dystrophin-deficient mdx mice have a very mild
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phenotype that only moderately impacts muscle func-
tion and survival [11,12].
How are zebrafish models of muscle
disease made?
There are three primary techniques for generating
zebrafish models of muscle disease, with the basic
overall strategy centered on manipulating a gene in a
manner analogous to what is observed in human
patients. Morpholino-based gene knockdown is a rapid
but transient strategy, forward genetic screens identify
germline mutations primarily based on muscle-related
phenotypes, and genome editing techniques create tar-
geted mutations in specific genes of interest. Despite
some limitations, particularly related to recapitulating
dominant mutations and specific point mutations,
these techniques have been used with great success to
model numerous muscle diseases (Table 1).
Morpholino-mediated knockdown has emerged as an
exceptionally useful technology, particularly for exam-
ining gene loss of function in zebrafish embryos
(although some dominant muscle diseases have been
modeled as well with morpholinos). This is largely
because of the rapidity by which ‘morphant’ zebrafish
can be created and analyzed. Morpholinos are synthetic
oligonucleotides similar to RNA with an uncharged
morpholino ring in place of a ribose. When targeted
against the start codon or splice sites of a gene of inter-
est, morpholinos can transiently reduce or eliminate
protein expression by inhibiting translation or pre-
mRNA processing. Morpholinos provide a means to
knock down gene expression quickly and with relatively
low cost. Most notably, as discussed below, morpholi-
no-mediated gene manipulation has emerged as a vital
approach for validating new gene mutations discovered
by next generation sequencing [4,5,13].
Because of their widespread use, it is important to
point out some of the caveats associated with mor-
pholinos in zebrafish. Many genes are duplicated in
the teleost genome, making it critical to look carefully
for multiple putative orthologs to a human gene of
interest when designing a knockdown experiment.
Morpholino knockdown is transient, and the efficacy of
morpholinos typically fades by 3 days post fertilization.
Gene knockdown may only be partial in many cases,
making it important to confirm loss of expression using
western blot or antibody staining. Additionally, mor-
pholinos may have off-target effects. To ensure that a
phenotype is gene-specific, careful validation of mor-
pholino knockdown is necessary. Controls for morpho-
lino experiments include injecting a mismatched control,
using multiple morpholinos targeted to the same gene,
and rescuing a morpholino phenotype with co-injection
of capped mRNA.
Forward genetic screens have proved to be an excel-
lent source of zebrafish mutants that model human dis-
ease. The first muscle mutants emerged from the
original ENU mutagenesis-based screen by N€usslein-




Fig. 1. Properties of zebrafish skeletal muscle. (A) Toluidine blue stained semi-thin longitudinal section from a 3-day-old zebrafish (209).
Note the obvious striations corresponding to the Z lines as well as the rare, eccentric nuclei. The thick vertical lines connecting the
myofibers are the myotendinous junctions. (B) Electron microscopy of 7-day-old zebrafish skeletal muscle. All the salient features of
mammalian muscle (Z bands, sarcomeres, thin and thick filaments, triad) are observed in fish muscle at this age (10 5009). (C)
Immunostaining of an isolated myofiber from a 3-day-old zebrafish (1209). Green is tropomodulin and red is actinin. This co-stain highlights
the ability to detect and visualize common markers of skeletal muscle structure. (D) Maximal force generation curve for wild-type (black)
and candyfloss (gray) embryos. These curves recapitulate force curves measured in mouse muscle and human myofibers.
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zebrafish mutant strains for dystrophin (sapje), titin
(runzel) and laminin a2 (candyfloss) [14,15]. More
recently, ENU and transposon-based screens have been
performed by Kunkel and Beggs (using birefringence as
a screen) and by Kuwada and colleagues (using
impaired motility as the output) and have resulted in the
identification of several strains with mutations in mus-
cular dystrophy and congenital myopathy genes [16–19].
Finally, the Wellcome Trust Sanger Institute has created
an emerging source of genetic mutants based on a
saturating ENU mutagenesis screen (http://www.
sanger.ac.uk/Projects/D_rerio/zmp/). Their mutation
resource contains a large bank of strains with mutations
that are identified based on a gene sequencing strategy
called TILLING. By using TILLING, they have identi-
fied mutations in several genes associated with human
muscle disease, although only a few resulting mutant
strains have been characterized (including nebhu2849 and
dag1hu3072) and the majority of the strains have yet to be
analyzed [20,21].
Until recently, there has not been a method for the
targeted generation of stable zebrafish knockouts.
However, new advances in genome editing technologies
have made it possible to generate gene-specific lesions
in the zebrafish genome. Two of these technologies,
zinc finger nucleases (ZFNs) and transcription activa-
tor-like effector nucleases (TALENs), utilize the non-
specific cleavage domain of the FokI endonuclease to
introduce a double-stranded break in genomic DNA.
In the case of ZFNs, these cleavage domains are
targeted to a precise genomic location by a pair of
DNA binding zinc finger domain assemblies [22].
TALENs are a similar form of genomic editing that
utilize DNA binding domains from transcription acti-
vator-like (TAL) effectors, and Ekker and colleagues
have developed a publicly available TALEN toolkit
for targeting the zebrafish genome [23,24]. Both ZFNs
and TALENs have been successfully used to generate
somatic and germline mutations in zebrafish embryos;
however, efficiently engineering a target-specific
Table 1. Zebrafish models of human muscle diseases.
Human gene Zebrafish gene Zebrafish model Reference Human condition
DMD dmd Morpholino [4] Duchenne muscular dystrophy
Mutant (sapje) [11,59]
Mutant (sapje-like) [34]
LAMA2 lama2 Mutant (caf) [13] Congenital muscular dystrophy (MDC1A)
Mutant (cl501) [17]
ITGA7 itga7 Morpholino [60] Congenital muscular dystrophy
LMNA lmna Morpholino [61,62] Multiple forms of dystrophy
COL6A1 col6a1 Morpholino [9] Ullrich congenital muscular dystrophy; Bethlem myopathy
COL6A3 col6a3 Morpholino [9] Ullrich congenital muscular dystrophy; Bethlem myopathy
DUX4 Overexpression [63, 64] Facioscapulohumeral muscular dystrophy
DNAJB6 dnajb6b Morpholino [65] Limb-girdle muscular dystrophy
DAG1 dag1 Morpholino [3] Limb-girdle muscular dystrophy (MDDGC9)
Mutant [16]
SGCD sgcd Morpholino [61,66,67] Limb-girdle muscular dystrophy
TCAP tcap Morpholino [61,68] Limb-girdle muscular dystrophy
DYSF dysf Morpholino [32,56] Myoshi myopathy; limb-girdle muscular dystrophy
POMT1 pomt1 Morpholino [43] Multiple forms of dystroglycanopathy
POMT2 pomt2 Morpholino [43] Multiple forms of dystroglycanopathy
FKRP fkrp Morpholino [21,40,41,69] Multiple forms of dystroglycanopathy
FKTN fktn Morpholino [21,69] Multiple forms of dystroglycanopathy
ISPD ispd Morpholino [46] Multiple forms of dystroglycanopathy
B3GNT1 b3gnt1 Morpholino [45] Walker–Warburg syndrome
GTDC2 gfdc2 Morpholino [44] Walker–Warburg syndrome
MTM1 mtm1 Morpholino [7] Myotubular myopathy
DNM2 Overexpression [70] Centronuclear myopathy
CCDC78 ccdc78 Morpholino [36] Congenital myopathy with internal nuclei and cores
NEB neb Morpholino [20] Nemaline myopathy
RYR1 ryr1b Mutant (ryr) [5] Multiple forms of congenital myopathy
SEPN1 sepn1 Morpholino [71,72] Multiple forms of congenital myopathy
DES desma Morpholino [61,73] Myofibrillar myopathy
desmb Morpholino [73]
CAV3 cav3 Morpholino [74] Caveolinopathies
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domain remains a bottleneck with both technologies.
A third technology utilizing bacterial CRISPR (clus-
tered regularly interspaced short palindromic repeats)
offers a promising alternative approach for inducing
targeted lesions in genomes [25,26]. CRISPR-based
targeting is RNA guided, bypassing some of the tech-
nical challenges involved in assembling appropriately
targeted ZFNs or TALENs. In zebrafish embryos,
CRISPR-based targeting has been shown to induce
targeted gene lesions in somatic cells with high effi-
ciency [27,28]. These new genome editing technologies
open up exciting avenues for zebrafish research, and
while muscle disease mutants have yet to be published,
they promise ultimately to be a transformative technol-
ogy in the generation of zebrafish models.
How are zebrafish models of muscle
disease analyzed?
As the number of zebrafish models for muscle disease
expands, a useful repertoire of techniques has been
developed in parallel for the analysis of muscle struc-
ture and function in zebrafish. First, developing zebra-
fish embryos exhibit highly stereotyped motor
behaviors that can be easily measured without the
need for special equipment [29]. Zebrafish embryos
begin coiling in a steady rhythmic pattern independent
of stimulation within the first day of life, providing a
simple measure of early slow-muscle-dependent muscle
function (Video S1) [7,9,20]. By 2 days post fertiliza-
tion, zebrafish embryos have developed a robust
escape response, rapidly swimming away from
mechanical stimuli (Video S2). Beginning at approxi-
mately 3 days post fertilization, larvae begin swimming
spontaneously and swim behaviors such as velocity
and turn frequency can be precisely quantified, espe-
cially through the use of proprietary imaging systems
like the Noldus DanioVision or the Viewpoint Zebra-
box. Together, these sequential motor behaviors pro-
vide simple and non-invasive measures of muscle
function and can thus serve as a platform for assessing
pharmacological and genetic interventions.
A number of zebrafish muscle studies have utilized
electrophysiological and biomechanical measurements
adapted from other model organisms. Several studies
have used in vivo patch clamp recording of larval skele-
tal muscle to establish whether a motor defect is caused
by defects in the central nervous system, the neuromus-
cular junction or the muscle fiber itself. To characterize
the relatively relaxed and accordion behavioral mutants,
Kuwada and colleagues analyzed the fictive swimming
response from both mutants and demonstrated normal
rhythmic input to the muscle in response to tactile stim-
ulation, showing that the primary functional defect
must be downstream of myofiber excitation from the
nervous system and neuromuscular junction [5,30]. Sim-
ilarly, injecting current into zebrafish muscle can evoke
contractions, and this technique has been used to mea-
sure muscle fatigue and relaxation in models of muscle
disease [7,30,31]. To directly measure muscle force gen-
eration, Brooks and colleagues developed a novel sys-
tem adapted from studies of murine muscle (Fig. 1D).
Using this system, they showed that a zebrafish model
of nemaline myopathy exhibits defects in contractile
properties nearly identical to those observed in nebulin
knockout mice and patient myofibers [20].
In addition to these functional measures of muscle
output, the striking similarities between fish and mam-
malian muscle has allowed important insights to be
gained from the analysis of zebrafish muscle using
both standard light microscopy analysis and transmis-
sion electron microscopy. Skeletal muscle can be
readily visualized in whole zebrafish using immunohis-
tochemistry or by using fluorescent markers driven by
muscle-specific promoters. Furthermore, the transpar-
ency of zebrafish embryos permits elegant optical
assays of muscle structure and function that would
not be possible in mammalian systems. Roostalu and
Strahle recently used high-resolution imaging to visu-
alize real-time membrane resealing in myofibers from
whole embryos, elucidating a sequential repair pro-
gram that occurs following sarcolemmal damage [32].
In vivo calcium imaging is another optical assay that
has provided insight into the nature of muscle defects.
Calcium flux in zebrafish myofibers is monitored
in vivo by injecting embryos with chemical (such as
dextran green) or genetically encoded calcium indica-
tors (such as Gcamp3), which can reveal defects in cal-
cium release or uptake [5,30].
One notable observation in developing zebrafish
muscle is that myofiber integrity can be easily viewed
using an optical phenomenon called birefringence.
When viewed under polarized light, detached myofi-
bers appear as dark patches in the skeletal muscle of
zebrafish embryos (Fig. 2). This phenomenon can be
directly quantified to measure loss of muscle integrity
in dystrophic larval muscle, and it has been particu-
larly useful in identifying novel muscle mutants in for-
ward screens and for testing therapies in known
dystrophy models [14,33,34]. Figure 2 depicts birefrin-
gence patterns for several well-characterized mutants.
This simple visual assay can be combined with other
measures of muscle integrity to provide substantial
insight into the dynamics of myofiber damage, retrac-
tion and death in dystrophic mutants. Evans blue dye,
a small molecule that only enters damaged myofibers,
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can be injected into zebrafish larvae to assay for sarco-
lemmal damage. Currie and colleagues have visualized
myofiber detachment in real time in candyfloss and
sapje dystrophic mutants by anesthetizing embryos for
the first 3 days of life, which preserved muscle integrity
by eliminating any muscle contraction during develop-
ment [8,13]. When anesthetic was washed out, fish
embryos embedded in agarose or methylcellulose con-
tract against surrounding media, inducing myofiber
detachment.
For experiments that cannot easily be performed in
an intact embryo, myofibers from the developing
zebrafish can be isolated and maintained ex vivo [34a].
Such preparations contain a mixture of myofibers and
other cell types, with myofibers representing the pre-
dominant cellular subtype. A range of experimentation
is feasible on isolated myofibers – including immuno-
cytochemistry, calcium imaging and electrophysiologi-
cal recording – and these preparations can allow more
precise measurements of myofiber size and protein
subcellular localization.
Models of muscle disorders
As summarized in Table 1, zebrafish have provided
useful models for many different muscle disorders.
Recent reviews, in particular by Peter Currie, have
extensively summarized several of these models [10,35].
While we present a brief listing of the major available
models in Table 1, this review will instead focus on a
few notable studies that reflect the power of the zebra-
fish to provide insight into muscle disease.
The zebrafish and new gene discovery:
the perfect partner for next
generation sequencing
It is estimated that the genetic basis of disease is not
known for 25–50% of all genetic muscle disorders.
This knowledge gap presents a significant barrier to
clinical practice and to research into disease pathogen-
esis and therapy development. Next generation
sequencing, including especially whole exome capture
followed by massively parallel sequencing, is rapidly
filling in the missing genetic pieces. A particular chal-
lenge with next generation sequencing, however, is that
it identifies numerous variants of unclear significance
that are not present in the existing variant databases.
Given that sequencing efforts are often focused on iso-
lated probands with a similar disease or small families
with very rare myopathies, identifying the true patho-
genic variants is often difficult in the absence of sup-
porting experimentation. The zebrafish has turned out
to be the ideal system for validating novel variants as
it provides a rapid way of genetically modeling and
testing a newly identified putative mutation.
Fig. 2. Birefringence in representative
zebrafish models of human muscle
disease. Left, Bright-field images of the
trunk and tail regions of the following
zebrafish models: wild-type (WT),
candyfloss (lama2 mutant, caf), sapje
(dystrophin mutant, sap), relatively relaxed
(RYR1 mutant, ryr) and neb (nebulin
mutant). Right, Birefringence images as
obtained by viewing zebrafish with a plane
polarizing filter. Note the patchy
birefringence of caf and sap, indicative of
muscle detachment in these modes, and
the reduced birefringence in neb,
indicative of the generalized and global
sarcomeric disorganization.
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There are now multiple examples, both in the muscle
literature and for other monogenetic disorders, where
zebrafish modeling has proved critical for the valida-
tion of a new gene mutation. We present a recent
example from our laboratory for a novel congenital
myopathy, and an example from Hans van Bokhoven
and colleagues describing a new gene associated with a
severe form of congenital muscular dystrophy.
CCDC78 mutation as the cause of a unique
congenital myopathy
We identified five individuals in a three-generation
dominant pedigree with moderate distal weakness,
excessive fatigue, and a muscle biopsy with the unu-
sual combination of excessive central nuclei, core-like
lesions, and desmin and actin accumulations [36]. We
used the combination of single nucleotide polymor-
phism linkage on the pedigree and whole exome
sequencing of two affected individuals to identify a
splice site sequence variant in the previously uncharac-
terized gene CCDC78. Based on RT-PCR data from
patient lymphoblastoid cells, we predicted that this
variant resulted in disease by allowing inclusion of an
in-frame intron of CCDC78. To validate the pathoge-
nicity of this variant, we developed a morpholino to
zebrafish ccdc78 targeting the exon–intron boundary
affected by the human sequence variant. Injection of
this morpholino into the developing zebrafish results
in aberrant processing of ccdc78 RNA, with inclusion
of the in-frame intron and production of a higher
molecular protein. The consequences associated with
this morpholino included impaired motor function
and abnormal larval morphology. Most notably, the
morpholino-induced histopathological changes in the
muscle, including myofibrillar disruption, triad abnor-
malities, and desmin and RYR1 accumulations, mirror
exactly the findings observed in the patient biopsies.
The similarities in both RNA processing and histopa-
thology in the zebrafish morphants enabled us to
conclude that the sequence variant in CCDC78 identi-
fied in the patients was the cause of disease.
Mutations in ISPD cause Walker–Warburg
syndrome
Mutant and morphant zebrafish have provided excep-
tionally useful models for a clinically diverse group of
muscle disorders known as dystroglycanopathies,
recessive disorders characterized by reduced O-man-
nose glycosylation of a-dystroglycan (DAG1). The phe-
notypes of dystroglycanopathies range from relatively
mild limb-girdle muscular dystrophy to Walker–
Warburg syndrome, a severe form of congenital mus-
cular dystrophy associated with eye and brain defects.
DAG1 plays an essential role in mammalian develop-
ment, limiting the usefulness of mouse models in
studying dystroglycanopathies, and complete knockout
of dystroglycan or certain dystroglycan processing
genes leads to embryonic lethality in mice [37–39].
While the dag1 glycosylation pathway appears to be
largely conserved in zebrafish, it is not essential for
early development, and knockdown of most known
dystroglycanopathy genes have been shown to recapit-
ulate many aspects of human disorders [21,40–45].
Recently, van Bokhoven and colleagues identified
mutations in the ISPD gene in individuals from nine
families with Walker–Warburg-like features [46]. To
elucidate the role of ISPD in this disorder, they
injected zebrafish with morpholinos to ispd. Consistent
with histopathology in patient muscle and other mod-
els of dystroglycanopathy, ispd morphants exhibit
hypoglycosylation of dag1. The ispd morphants also
have a dystrophic muscle phenotype, and sarcolemma
integrity is disrupted. In addition to muscle abnormali-
ties, zebrafish recapitulate a severe hydrocephalus
phenotype seen in patients. These findings demonstrate
the value of zebrafish in validating and characterizing
rare variants associated with muscle disease. Of note,
morpholino knockdown has also been used to func-
tionally validate mutations in GTDC2 and B3GNT1,
two additional genes in which mutations were identified
in patients with Walker–Warburg and related dystrogly-
canopathies. Both gtdc2 and b3gnt1 morphants exhib-
ited severe muscle, eye and brain defects, as well as
reduced glycosylation of a-dystroglycan [44,45].
The zebrafish as a tool for identifying
novel pathogenic mechanisms
Much of what is known concerning disease pathogene-
sis in most skeletal muscle disorders has been derived
from the combination of cell culture studies and exper-
imentation in murine models. The zebrafish has
recently entered the arena of pathogenesis studies and
has helped reveal novel aspects of disease that were
not previously detected in mice or cultured cells. Here
we describe findings in two such studies and highlight
the contributions they have made to the understanding
of pathomechanisms in human muscle disease.
Vitamin-based rescue in a zebrafish model of
muscular dystrophy
Using a dag1 morphant zebrafish model, Henry and
colleagues demonstrated a remarkable rescue of
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dystrophic muscle by supplementation with coenzyme
NAD+ [47]. In untreated dag1 morphants, muscle
degeneration began at 3 days post fertilization. Mor-
phants supplemented with NAD+ exhibited reduced
fiber detachment, improved organization of the sur-
rounding basement membrane and increased swim
speed in touch-evoked escape responses. Intriguingly,
the group achieved a similar rescue by the simple addi-
tion of a vitamin supplement containing niacin, a pre-
cursor to NAD+.
To identify the mechanism underlying the protective
effect of NAD+ supplementation, they used morpholi-
nos against components of the dystrophin–glycopro-
tein complex or the a7b1 integrin complex, two of the
major adhesion complexes in muscle. Although they
demonstrated that full NAD+-mediated rescue is
dependent on expression of either dag1 or integrin a7,
they find that an additional receptor (integrin a6) is
also required for rescue. These findings suggest that
integrin a6 may be part of a previously unrecognized
integrin adhesion complex in skeletal muscle. There-
fore, along with identifying a novel therapeutic strat-
egy, this study highlights the utility of the zebrafish
model in teasing out the molecular underpinnings of
muscle disorders.
Oxidative stress in a zebrafish model of RYR1-
related myopathies
Ryanodine receptors are calcium release channels that
play a critical role in muscle excitation and contrac-
tion. Mutations in ryanodine receptor 1 (RYR1) cause
a diverse range of dominant and recessive muscle dis-
orders, including especially central core disease and
minicore myopathy [48–53]. The spontaneous relatively
relaxed (ryr) zebrafish mutant, identified by a slow
swimming phenotype, carries an insertional mutation
in ryr1b, the fast-twitch fiber zebrafish ortholog to
RYR1 [5]. Using a differential RNA microarray based
approach to identify expression, our laboratory found
that ryr zebrafish exhibit upregulation of numerous
genes associated with cellular stress, and follow-up
biochemical studies uncovered increased intracellular
oxidant activity [54]. Based on this result, ryr zebrafish
were treated with the anti-oxidant N-acetylcysteine
(NAC), and treated larvae exhibited significant
increases in swimming behavior and substantial
improvements in muscle histopathology. These results
were corroborated by Ana Ferreiro and colleagues [54]
by the observation of increased oxidative stress in
myotubes derived from patients with RYR1-related
myopathies, suggesting that this is a clinically relevant
pathomechanism, and NAC is now considered an
excellent therapeutic candidate for patients with RYR1
mutations.
Zebrafish as an ideal system for novel
drug discovery
Large-scale drug screens are not feasible in mammals
due to cost and time required but are well suited to
invertebrate models or to cultured cells. However, such
assays in invertebrates or cells are often far removed
from the human disease and often lack functional out-
come measures that provide relevance for the identifi-
cation of drugs that will ultimately translate to the
clinical setting. In principle, the zebrafish offers the
ideal combination of invertebrate advantages (small
size, rapid development, large numbers) and vertebrate
biological relevance. In practice, only one large-scale
drug screen (described below) has been published to
date using a zebrafish model of muscular dystrophy.
However, the success of zebrafish screens in other dis-
ease spheres – in particular melanoma, where a novel
drug identified in a large-scale screen has successfully
translated to the clinic – has engendered optimism that
screens in models of muscle disease will yield similar
results [55].
Kunkel and colleagues performed a large-scale drug
screen in dystrophin-null zebrafish (sapje and sapje-
like), using birefringence (which is a marker of muscle
integrity and is markedly abnormal in sapje) as the
outcome measure [56]. This straightforward readout
permitted the rapid screening of 1120 chemicals for
compounds that prevented the loss of muscle organiza-
tion that typically occurs in sapje during the first few
days of development. In the initial screen, they tested
pools of eight chemicals on embryos from heterozy-
gous sapje parents, with the expectation that approxi-
mately 25% of embryos would exhibit abnormal
birefringence when treated with a pool of non-effective
compounds. Chemical pools that had reduced numbers
of embryos with abnormal birefringence (≤ 7.5%) were
then separated and individually screened to determine
which compounds were associated with the decrease.
Using this two-step screening strategy, they identified
seven compounds that preserved muscle integrity in
sapje mutants. They further demonstrated that long-
term treatment with one compound, a phosphodiester-
ase (PDE) inhibitor, was able to both extend survival
and restore muscle integrity in older affected sapje
zebrafish. Given that PDE inhibitors have been shown
to modulate disease in mouse models of Duchenne
muscular dystrophy and in Duchenne muscular dystro-
phy patient myotubes, this result provides important
proof-of-principle of the suitability of zebrafish as a
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tool for drug development [57,58]. In addition, the
study highlights the tremendous potential of the zebra-
fish in large-scale drug screens, and provides a path
forward for drug discovery in zebrafish models of mus-
cle disease.
Conclusions and prospective
In this review, we have outlined the utility of the
zebrafish as a model for human muscle diseases and
have highlighted several recent publications that illu-
minate the power of the model for gene discovery and
therapy development. At present, the most important
area of impact for the fish model has been as a tool
for validating new mutations discovered by next gen-
eration sequencing, and we predict that such experi-
mentation will become increasingly important as
whole exome and genome sequencing are applied more
extensively to isolated probands and individual fami-
lies. An ongoing challenge related to the application
of zebrafish to mutation validation is the proper use
of the system. We believe the strongest and most sup-
port outcomes to measure in the fish are those that
reflect on specific features of the human disease, such
as dystrophic changes (like patchy birefringence) or
specific histopathological features (like rods or actinin
accumulations in models of nemaline myopathy), and
not on non-specific outcomes like motor function and
overall fish morphology. In addition, while speed is
often desired for new mutation validation, the need
for well considered and controlled zebrafish experi-
ments is paramount to reduce the chance that non-
pathogenic variants are falsely considered to be disease
causing.
Moving forward, perhaps the most exciting area
for fish research relates to therapy development, as
the ability to perform large-scale chemical and/or
genetic screens in the zebrafish has amazing poten-
tial. To date, research has only scratched the surface
of this potential, and it is exciting to speculate that
such experimentation, because it is based on whole
organism screening, will yield unexpected disease
insights and novel therapeutic targets. The true
translatability of the zebrafish, however, is still an
unknown, and will not truly be understood until tar-
gets first identified in the fish are brought to the
clinical trial arena.
In all, we anticipate widespread and increased use of
the zebrafish to study muscle disease and to develop
therapies, as more and more researchers discover the
ease of use of the system, the facility for genetic
manipulation and the power of the muscle-related out-
comes it provides.
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